Cited by 874Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization

Open access

Roe, Matthew T., Armstrong, Paul W., Fox, Keith A.A., White, Harvey D., Prabhakaran, Dorairaj, Goodman, Shaun G., Cornel, Jan H., Bhatt, Deepak L., Clemmensen, Peter, Martinez, Felipe, Ardissino, Diego, Nicolau, Jose C., Boden, William E., Gurbel, Paul A., Ruzyllo, Witold, Dalby, Anthony J., McGuire, Darren K., Leiva-Pons, Jose L., Parkhomenko, Alexander, Gottlieb, Shmuel, Topacio, Gracita O., Hamm, Christian, Pavlides, Gregory, Goudev, Assen R., Oto, Ali, Tseng, Chuen-Den, Merkely, Bela, Gasparovic, Vladimir, Corbalan, Ramon, Cinteză, Mircea, McLendon, R. Craig, Winters, Kenneth J., Brown, Eileen B., Lokhnygina, Yuliya, Aylward, Philip E., Huber, Kurt, Hochman, Judith S., Ohman, E. Magnus·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1205512

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated. METHODS: In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel. RESULTS: At a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05; P=0.21). Similar results were observed in the overall population. The prespecified analysis of multiple recurrent ischemic events (all components of the primary end point) suggested a lower risk for prasugrel among patients under the age of 75 years (hazard ratio, 0.85; 95% CI, 0.72 to 1.00; P=0.04). Rates of severe and intracranial bleeding were similar in the two groups in all age groups. There was no significant between-group difference in the frequency of nonhemorrhagic serious adverse events, except for a higher frequency of heart failure in the clopidogrel group. CONCLUSIONS: Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed. (Funded by Eli Lilly and Daiichi Sankyo; TRILOGY ACS ClinicalTrials.gov number, NCT00699998.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1205512

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
A Prospective Natural-History Study of Coronary Atherosclerosis
Stone, G. W., Maehara, A., Lansky, A. J., Bruyne, B. D., Cristea, E., Mintz, G. S., Mehran, R., McPherson, J., Farhat, N. Z., Marso, S. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1002358 · Cited by 3,301
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Authors Task Force Members, Hamm, C. W., Bassand, J., Agewall, S., Bax, J. J., Boersma, E. H., Bueno, H., Caso, P., Dudek, D., Gielen, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr236 · Cited by 3,096
Self-citation
Clopidogrel for Coronary Stenting
Gurbel, P. A., Bliden, K. P., Hiatt, B. L., & O’Connor, C. M. (2003) · Circulation · doi:10.1161/01.cir.0000072771.11429.83 · Cited by 1,544
Self-citation
ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation
Hamm, C. W., Bassand, J., Agewall, S., Bax, J. J., Boersma, E. H., Bueno, H., Caso, P., Dudek, D., Gielen, S., Huber, K., et al. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.11.006 · Cited by 1,062
Self-citation
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., de Werf, F. V., White, H. D., Aylward, P. E., Wallentin, L. C., Chen, E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109719 · Cited by 756
Self-citation
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
Wright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H. M., Lincoff, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.011 · Cited by 513
Treatments, Trends, and Outcomes of Acute Myocardial Infarction and Percutaneous Coronary Intervention
Roe, M. T., Messenger, J. C., Weintraub, W. S., Cannon, C. P., Fonarow, G. C., Dai, D., Chen, A. Y., Klein, L. W., Masoudi, F. A., McKay, C. R., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.008 · Cited by 447
Self-citation

Flagged first, then by citations

Show all 18 references

Sorted by citations

Items 201–300 of 873

Ethnic Differences in Oral Antithrombotic Therapy
Cho, H., Kang, J., Kim, H.-S., & Park, K. W. (2020) · Korean Circulation Journal · doi:10.4070/kcj.2020.0098 · Cited by 32
Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada : A real‐world evidence study
Chen, G., Farris, M. S., Cowling, T., Pinto, L. A., Rogoza, R. M., Mackinnon, E. S., Champsi, S., & Anderson, T. J. (2021) · Clinical Cardiology · doi:10.1002/clc.23732 · Cited by 32
Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH Registry
Ducrocq, G., Bhatt, D. L., Labreuche, J., Corbalan, R. L., Porath, A., Gao, R., Панченко, Е. П., Cs, L., Ikeda, Y., Goto, S., et al. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487313501278 · Cited by 30
Self-citation
The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease
Nathan, A. S., Sen, S., & Yeh, R. W. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1315101 · Cited by 31
Systematic review with meta‐analysis: the risk of gastrointestinal bleeding in patients taking third‐generation P2Y12 inhibitors compared with clopidogrel
Guo, C., Chen, L., Chan, E. W., Cheung, K. S., Isshiki, T., Wong, I. C. K., & Leung, W. K. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15059 · Cited by 34
The Two-way Relationship Between Cancer and Atherosclerosis
Raposeiras‐Roubín, S., & Cordero, A. (2019) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2018.12.010 · Cited by 32
Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial
Cornel, J. H., Ohman, E. M., Neely, B., Clemmensen, P. M., Sritara, P., Zamoryakhin, D., Armstrong, P. W., Prabhakaran, D., White, H. D., Fox, K. A. A., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.04.011 · Cited by 30
Self-citation
Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease
Husted, S., Wallentin, L. C., Andreotti, F., Arnesen, H., Bachmann, F., Baigent, C., Collet, J., Halvorsen, S., Huber, K., Jespersen, J., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-09-0703 · Cited by 30
Self-citation
Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome
Shah, R., Abdul-Rashid, H. A., Hwang, I., Fan, T. M., Khouzam, R. N., & Reed, G. L. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.03.011 · Cited by 29
Elevated FURIN Levels in Predicting Mortality and Cardiovascular Events in Patients with Acute Myocardial Infarction
Wang, Y. K., Tang, J. N., Han, L., Liu, X. D., Shen, Y. L., Zhang, C. Y., & Liu, X. B. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154323 · Cited by 29
Updates in Antiplatelet Agents Used in Cardiovascular Diseases
Cheng, J. W. M. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413499971 · Cited by 29
Comparison of Five-Year Outcome of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Triple-Vessel Coronary Artery Disease (from the Coronary Revascularization Demonstrating Outcome Study in Kyoto PCI/CABG Registry Cohort-2)
Shiomi, H., Morimoto, T., Furukawa, Y., Nakagawa, Y., Tazaki, J., Sakata, R., Okabayashi, H., Hanyu, M., Shimamoto, M., Nishiwaki, N., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.03.040 · Cited by 29
Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study
Goodman, S. G., Nicolau, J. C., Requena, G., Maguire, A., Blankenberg, S., Chen, J. Y., Granger, C. B., Grieve, R., Pocock, S., Simon, T., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.062 · Cited by 29
Self-citation
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome
Roe, M. T., Cyr, D. D., Eckart, D., Schulte, P. J., Morse, M. A., Blackwell, K., Ready, N., Zafar, S. Y., Beaven, A., Strickler, J. H., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv611 · Cited by 28
Self-citation
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Fox, K. A. A., Eikelboom, J. W., Anand, S. S., Bhatt, D. L., Bosch, J., Connolly, S. J., Harrington, R. A., Steg, P. G., & Yusuf, S. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy347 · Cited by 28
Self-citation
Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial
Welsh, R. C., Sidhu, R. S., Cairns, J. A., Lavi, S., Kedev, S. A., Moreno, R., Cantor, W. J., Stankovic, G. R., Meeks, B., Yuan, F., et al. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.04.026 · Cited by 28
Intelligent Platelet Morphometry
Zhou, Y., Isozaki, A., Yasumoto, A., Xiao, T., Yatomi, Y., Lei, C., & Goda, K. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.12.012 · Cited by 27
Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
Roffi, M., Patrono, C., Collet, J., Mueller, C. E., Valgimigli, M., Bax, J. J., Borger, M. A., Chew, D. P., Hasenfuss, G. P., Kjeldsen, K. P., et al. (2015) · Cited by 27
Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease
Romano, S., Buccheri, S., Mehran, R., Angiolillo, D. J., & Capodanno, D. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1524869 · Cited by 27
Oral dual antiplatelet therapy: what have we learnt from recent trials?
Montalescot, G., & Sabatine, M. S. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv377 · Cited by 27
Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis
Tarantini, G., Ueshima, D., D’Amico, G., Masiero, G., Musumeci, G., Stone, G. W., & Brener, S. J. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.09.012 · Cited by 26
Guía ESC 2020 sobre el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST
Collet, J., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J. K., Bhatt, D. L., Dendale, P., Dorobanţu, M., Edvardsen, T., Folliguet, T. A., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.12.024 · Cited by 38
Self-citation
Development and Initial Validation of a Frailty Score for Pediatric Patients with Congenital and Acquired Heart Disease
Studyvin, S., Birnbaum, B. F., Staggs, V. S., Gross‐Toalson, J., Shirali, G. S., Panchangam, C., & White, D. A. (2022) · Pediatric Cardiology · doi:10.1007/s00246-022-03045-1 · Cited by 27
Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications
Song, J. W., Soh, S., & Shim, J. (2017) · Korean Journal of Anesthesiology · doi:10.4097/kjae.2017.70.1.13 · Cited by 27
Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials
Fanaroff, A. C., Clare, R. M., Pieper, K. S., Mahaffey, K. W., Melloni, C., Green, J. B., Alexander, J. H., Jones, W. S., Harrison, R. W., Mehta, R. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037202 · Cited by 26
Self-citation
Safety of Reloading Prasugrel in Addition to Clopidogrel Loading in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Loh, J. P.-Y., PENDYALA, L. K., Kitabata, H., Torguson, R., Chen, F., Kent, K. M., Satler, L. F., Suddath, W. O., Pichard, A. D., & Waksman, R. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.11.058 · Cited by 26
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study
Bhatt, D. L., Fox, K. M., Harrington, R. A., Leiter, L. A., Mehta, S. R., Simon, T., Andersson, M., Himmelmänn, A., Ridderstråle, W., Held, C., et al. (2019) · Clinical Cardiology · doi:10.1002/clc.23164 · Cited by 25
Self-citation
The Year in Atherothrombosis
Sanz, J., Moreno, P., & Fuster, V. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.06.045 · Cited by 27
Gastrointestinal Adverse Events after Dual Antiplatelet Therapy: Clopidogrel Is Safer than Ticagrelor, but Prasugrel Data Are Lacking or Inconclusive
Serebruany, V. L., DiNicolantonio, J. J., Can, M. M., Викторович, П. И., & Kuliczkowski, W. (2013) · Cardiology · doi:10.1159/000350961 · Cited by 26
Novel Anti-platelet Agents: Focus on Thrombin Receptor Antagonists
Brito, F. D. S., & Tricoci, P. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9454-3 · Cited by 27
The Use Pattern and Clinical Impact of New Antiplatelet Agents Including Prasugrel and Ticagrelor on 30-day Outcomes after Acute Myocardial Infarction in Korea: Korean Health Insurance Review and Assessment Data
Kim, C., Shin, D., Ahn, C., Kim, J., Kim, B., Ko, Y., Choi, D., Hong, M., Park, J., Lee, H. Y., et al. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0072 · Cited by 26
Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients
Mackman, N., Spronk, H. M. H., Stouffer, G. A., & Cate, H. T. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310048 · Cited by 29
La relación bidireccional entre el cáncer y la ateroesclerosis
Raposeiras‐Roubín, S., & Cordero, A. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2018.12.011 · Cited by 27
Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike
Franchi, F., Rollini, F., Park, Y., & Angiolillo, D. J. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.08.009 · Cited by 25
Antiplatelet Therapy and Cardiac Surgery: Review of Recent Evidence and Clinical Implications
FITCHETT, D. H., Mazer, C. D., Eikelboom, J. W., & Verma, S. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.02.014 · Cited by 26
Antiplatelet Management for Coronary Heart Disease: Advances and Challenges
Gillette, M., Morneau, K. M., Hoang, V., Virani, S. S., & Jneid, H. M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0581-6 · Cited by 25
P2Y12-ADP receptor antagonists: Days of future and past
Laine, M., Paganelli, F. F., & Bonello, L. (2016) · World Journal of Cardiology · doi:10.4330/wjc.v8.i5.327 · Cited by 26
Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications
Goli, R. R., Contractor, M. M., Nathan, A. S., Tuteja, S., Kobayashi, T., & Giri, J. S. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0698-2 · Cited by 25
Comprehensive Geriatric Assessment in the Management of Older Patients With Cardiovascular Disease
Singh, M., Spertus, J. A., Gharacholou, S. M., Arora, R. C., Widmer, R. J., Kanwar, A., Sanjanwala, R., Welle, G. A., & Al-Hijji, M. A. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.09.003 · Cited by 25
Editor’s Choice-Medically managed patients with non–ST-elevation acute myocardial infarction have heterogeneous outcomes, based on performance of angiography and extent of coronary artery disease
Feldman, L. J., Steg, P. G., Amsallem, M., Puymirat, É., Sorbets, E., Elbaz, M., Ritz, B., Hueber, A., Cattan, S., Piot, C. A., et al. (2016) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872615626354 · Cited by 25
Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes
Savonitto, S., Morici, N., Nozza, A., Cosentino, F., Filardi, P. P., Murena, E., Morocutti, G., Ferri, M., Cavallini, C., Eijkemans, M. J. C., et al. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117735493 · Cited by 24
Morphine, Oxygen, Nitrates, and Mortality Reducing Pharmacological Treatment for Acute Coronary Syndrome: An Evidence-based Review
de Alencar, J. N. (2018) · Cureus · doi:10.7759/cureus.2114 · Cited by 28
Frailty in cardiovascular disease: Screening tools
Zão, A., Magalhães, S., & Santos, M. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2018.05.019 · Cited by 25
Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach
Lattuca, B., Kernéis, M., Zeitouni, M., Cayla, G., Guedeney, P., Collet, J., Montalescot, G., & Silvain, J. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00663-y · Cited by 25
Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome
Roy, A., Roe, M. T., Neely, M. L., Cyr, D. D., Zamoryakhin, D., Fox, K. A. A., White, H. D., Armstrong, P. W., Ohman, E. M., & Prabhakaran, D. (2014) · Heart · doi:10.1136/heartjnl-2014-306389 · Cited by 23
Self-citation
Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention
Sullivan, K. R., Wellsted, D. M., Christopoulos, C., Farag, M., & Gorog, D. A. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-09-0712 · Cited by 24
2020 ESC Guidelines on acute coronary syndrome without ST-segment elevation
Arslan, F., Damman, P., Zwart, B., Appelman, Y., Voskuil, M., de Vos, A., van Royen, N., Jukema, J. W., Waalewijn, R. A., Hermanides, R. S., et al. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01593-4 · Cited by 24
Early and late recurrent cardiovascular events among high‐risk patients with an acute coronary syndrome: Meta‐analysis of phase III studies and implications on trial design
Chi, G., Lee, J., Kazmi, S. H. A., Fitzgerald, C., Montazerin, S. M., Kalaycı, A., Korjian, S., Heise, M. A., Deckelbaum, L. I., Libby, P., et al. (2022) · Clinical Cardiology · doi:10.1002/clc.23773 · Cited by 22
Self-citation
De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis
FILIPPO, O. D., Piroli, F., Bruno, F., Bocchino, P. P., Saglietto, A., Franchin, L., Angelini, F., Gallone, G., Rizzello, G., Ahmad, M., et al. (2024) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2023-112476 · Cited by 26
Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary intervention
Ahn, K. T., Seong, S.-W., Choi, U. L., Jin, S., Kim, J. H., Lee, J., Choi, S. W., Jeong, M. H., Chae, S. C., Kim, Y., et al. (2019) · Medicine · doi:10.1097/md.0000000000014833 · Cited by 24
Ticagrelor or Prasugrel in Acute Coronary Syndromes — The Winner Takes It All?
Jneid, H. M. (2019) · New England Journal of Medicine · doi:10.1056/nejme1911207 · Cited by 24
Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the ‘real world’
Almendro‐Delia, M., Ponce, E. B., Gómez-Domínguez, R., González-Matos, C. E., Lobo-González, M., Caballero-García, A., Hidalgo-Urbano, R. J., Cruz-Fernandez, M. J., & García-Rubira, J. C. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1139-5 · Cited by 23
A new paradigm shift in antithrombotic therapy
Pudusseri, A., Shameem, R., & Spyropoulos, A. C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00133 · Cited by 23
Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study
Luca, L. D., Leonardi, S., Smecca, I. M., Formigli, D., Lucci, D., Gonzini, L., Tuccillo, B., Olivari, Z., Gulizia, M. M., Bovenzi, F., et al. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv006 · Cited by 23
Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?
Sumaya, W., Geisler, T., Kristensen, S. D., & Storey, R. F. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1679903 · Cited by 23
Atrial Fibrillation and Coronary Artery Disease: A Long-Term Perspective on the Need for Combined Antithrombotic Therapy
Fanaroff, A. C., Li, S., Marquis‐Gravel, G., Giri, J., Lópes, R. D., Piccini, J. P., & Wang, T. Y. (2021) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.121.011232 · Cited by 24
Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Japanese Patients With Stable Coronary Artery Disease
Nishi, T., Ariyoshi, N., Nakayama, T., Fujimoto, Y., Sugimoto, K., Takahara, M., Wakabayashi, S., Koshizaka, M., Hanaoka, H., & Kobayashi, Y. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0546 · Cited by 23
Long-term outcomes for women versus men with unstable angina/non–ST-segment elevation myocardial infarction managed medically without revascularization: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial
Clemmensen, P. M., Roe, M. T., Hochman, J. S., Cyr, D. D., Neely, M. L., McGuire, D. K., Cornel, J. H., Huber, K., Zamoryakhin, D., White, H. D., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.06.011 · Cited by 23
Self-citation
Evaluation and Management of Chest Pain in the Elderly
Gupta, R., & Munoz, R. (2016) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2016.04.006 · Cited by 23
The risk of dyspnea in patients treated with third-generation P2Y12 inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials
Zhang, N., Xu, W., Li, O., & Zhang, B. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01419-y · Cited by 24
Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements
Becker, K. C. D., Kwee, L. C., Neely, M. L., Grass, E. A., Jakubowski, J. A., Fox, K. A. A., White, H. D., Gregory, S. G., Gurbel, P. A., Carvalho, L. D. P., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63263-6 · Cited by 23
Self-citation
Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis
Fei, Y., Lam, C. K., & Cheung, B. M. Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-73871-x · Cited by 23
Meta‐Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes
Mahaffey, K. W., Hager, R., WOJDYLA, D. M., White, H. D., Armstrong, P. W., Alexander, J. H., Tricoci, P., Lópes, R. D., Ohman, E. M., Roe, M. T., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001512 · Cited by 23
Self-citation
Targeting P-Selectin During Coronary Interventions
Alfonso, F., & Angiolillo, D. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.004 · Cited by 23
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: A meta-analysis of randomized trials
Tang, X., Fan, J., Meng, J., Chen, J., Yuan, J., & Yang, Y. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.01.017 · Cited by 22
Near-Real-Time Monitoring of New Drugs: An Application Comparing Prasugrel Versus Clopidogrel
Gagne, J. J., Rassen, J. A., Choudhry, N. K., Bohn, R. L., Patrick, A. R., Sridhar, G., Daniel, G. W., Liu, J., & Schneeweiß, S. (2014) · Drug Safety · doi:10.1007/s40264-014-0136-0 · Cited by 21
The Prognostic Impact of High On-Treatment Platelet Reactivity with Aspirin or ADP Receptor Antagonists: Systematic Review and Meta-Analysis
D’Ascenzo, F., Barbero, U., Bisi, M., Moretti, C., Omedè, P., Cerrato, E., Quadri, G., Conrotto, F., Biondi‐Zoccai, G., DiNicolantonio, J. J., et al. (2014) · BioMed Research International · doi:10.1155/2014/610296 · Cited by 22
Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease
Bonello, L., Laine, M., Lemesle, G., Puymirat, É., Dabry, T., Thuny, F., Paganelli, F. F., Aradi, D., Frère, C., Burtey, S., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1669426 · Cited by 22
Characteristics and outcomes of medically managed patients with non-ST-segment elevation acute coronary syndromes: Insights from the multinational EPICOR Asia study
Chin, C. T., Ong, T. K., Krittayaphong, R., Lee, S. W. L., Sawhney, J. P. S., Kim, H.-S., Garcia, A. A., Bueno, H., Pocock, S., Nhân, V. T., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.04.059 · Cited by 22
New Antithrombotics for Secondary Prevention of Acute Coronary Syndrome
Goto, S., & Tomita, A. (2014) · Clinical Cardiology · doi:10.1002/clc.22233 · Cited by 21
Dual Antiplatelet Therapy for Coronary Artery Disease
Lee, C. W. (2015) · Circulation Journal · doi:10.1253/circj.cj-14-1348 · Cited by 21
Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: Design of the randomized antarctic study
Cayla, G., Cuisset, T., Silvain, J., Henry, P., Leclercq, F., Carrié, D., Etienne, C. S., Belle, L., Rangé, G., Pouillot, C., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.07.026 · Cited by 21
Contemporary NSTEMI management: the role of the hospitalist
Pollack, C. V., Amin, A., Wang, T. S., Deitelzweig, S. B., Cohen, M. C., Slattery, D., Fanikos, J. R., DiLascia, C., Tuder, R. C., & Kaatz, S. (2019) · Hospital Practice · doi:10.1080/21548331.2020.1701329 · Cited by 22
Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments
Tantry, U. S., Navarese, E. P., Myat, A., Chaudhary, R., & Gurbel, P. A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1457649 · Cited by 21
Self-citation
Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries
Peyracchia, M., Saglietto, A., Biolè, C., Raposeiras‐Roubín, S., Abu‐Assi, E., Kinnaird, T. D., Ariza‐Solé, A., Liebetrau, C., Manzano‐Fernández, S., Boccuzzi, G. G., et al. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00373-1 · Cited by 21
Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction
Shen, L., Shah, B. R., Nam, A., Holmes, D. N., Alexander, K. P., Bhatt, D. L., Ho, P. M., Peterson, E. D., He, B., & Roe, M. T. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.009 · Cited by 21
Self-citation
Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’ patients
Gosling, R. C., Yazdani, M. F., Parviz, Y., Hall, I. R., Grech, E. D., Gunn, J. P., Storey, R. F., & Iqbal, J. (2017) · Platelets · doi:10.1080/09537104.2017.1280601 · Cited by 20
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy
Miller, M. M., Banville, J., Friends, T. J., Gagnon, M., Hangeland, J. J., Lavallée, J.-F., Martel, A. M., O'Grady, H. R., Rémillard, R., Ruediger, E. H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00186 · Cited by 20
Benefit–Risk Tradeoffs in Assessment of New Drugs and Devices
Kaul, S., Stockbridge, N., & Butler, J. (2020) · Circulation · doi:10.1161/circulationaha.120.048933 · Cited by 20
Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status
Pradhan, A. K., Tiwari, A., Caminiti, G., Salimei, C., Muscoli, S., Sethi, R., & Perrone, M. A. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19158977 · Cited by 20
Tailored antiplatelet therapy in stent assisted coiling for unruptured aneurysms: a nationwide registry study
Koh, J. S., Hwang, G., Park, J. C., Lee, C., Chung, J., Lee, S.-W., Kwon, H., Kim, S.-R., Kang, D.-H., Kwon, S. C., et al. (2023) · Journal of NeuroInterventional Surgery · doi:10.1136/jnis-2022-019571 · Cited by 20
The Year in Acute Coronary Syndrome
Giugliano, R. P., & Braunwald, E. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.041 · Cited by 21
Updates and Current Recommendations for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: What It Means for Clinical Practice
Cayla, G., Silvain, J., Collet, J., & Montalescot, G. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.01.003 · Cited by 20
Gastrointestinal bleeding in cardiac patients
Abraham, N. S. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000122 · Cited by 20
Comparative Review of Oral P2Y12 Inhibitors.
Koski, R. R., & Kennedy, B. (2018) · Europe PMC (PubMed Central) · Cited by 20
Optimal P2Y12 inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials
Montalto, C., Morici, N., Munafò, A. R., Mangieri, A., Mirizzi, A. M., D’Ascenzo, F., Oreglia, J., Latib, A., Porto, I., Colombo, A., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa101 · Cited by 20
Actualización en cardiopatía isquémica y cuidados críticos cardiológicos
Marín, F. R., Dı́az-Castro, Ó., Ruiz-Nodar, J. M., de la Villa, B. G., Sionís, A., López, J., Fernández‐Ortíz, A., & Martínez‐Sellés, M. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.10.007 · Cited by 18
Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry
Kurz, D. J., Radovanović, D., Seifert, B., Bernheim, A. M., Roffi, M., Pedrazzini, G. B., Windecker, S., Erné, P., & Eberli, F. R. (2015) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872614566946 · Cited by 19
Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel
Galeazzi, R., Olivieri, F., Spazzafumo, L., Rose, G., Montesanto, A., Giovagnetti, S., Cecchini, S., Malatesta, G., Pillo, R. D., & Antonicelli, R. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0555-1 · Cited by 19
Translation of experimental cardioprotective capability of P2Y12 inhibitors into clinical outcome in patients with ST-elevation myocardial infarction
Hjortbak, M. V., Olesen, K. K. W., Seefeldt, J. M., Lassen, T. R., Jensen, R. V., Perkins, A., Dodd, M., Clayton, T. C., Yellon, D. M., Hausenloy, D. J., et al. (2021) · Basic Research in Cardiology · doi:10.1007/s00395-021-00870-y · Cited by 19
A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice
Arockiam, S., Staniforth, B., Kepreotis, S., Maznyczka, A., & Bulluck, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311132 · Cited by 21
Guía de Práctica Clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable
Montalescot, G., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Sechtem, U. P., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.11.007 · Cited by 21
Clopidogrel, Prasugrel, or Ticagrelor? A Practical Guide to Use of Antiplatelet Agents in Patients With Acute Coronary Syndromes
Norgard, N. B., & DiNicolantonio, J. J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.07.2682 · Cited by 22
Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease
Park, Y., Franchi, F., Rollini, F., & Angiolillo, D. J. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0208 · Cited by 19
Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations
Covic, A. C., Genovesi, S., Rossignol, P., Kalra, P. A., Ortíz, A., Banach, M., & Burlacu, A. (2018) · BMC Medicine · doi:10.1186/s12916-018-1145-0 · Cited by 19
State of the art: Oral antiplatelet therapy
Gurbel, P. A., Myat, A., Kubica, J., & Tantry, U. S. (2016) · JRSM Cardiovascular Disease · doi:10.1177/2048004016652514 · Cited by 18
Self-citation
Individual Platelet Adhesion Assay: Measuring Platelet Function and Antiplatelet Therapies in Whole Blood via Digital Quantification of Cell Adhesion
Lopez-Alonso, A., Jose, B., Somers, M., Egan, K., Foley, D. P., Ricco, A. J., Ramström, S., Basabe‐Desmonts, L., & Kenny, D. J. (2013) · Analytical Chemistry · doi:10.1021/ac401076s · Cited by 18
Viewpoint: “Underutilisation of novel antiplatelet agents – myths, generics, and economics”
Fortmann, S. D., & Serebruany, V. L. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-10-0862 · Cited by 18
Dual Antiplatelet Therapy with Prasugrel or Ticagrelor Versus Clopidogrel in Interventional Cardiology
Clemmensen, P. M., Dridi, N. P., & Holmvang, L. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6444-2 · Cited by 18
Self-citation
Oral antiplatelet agents in cardiovascular disease
Pultar, J., Wadowski, P. P., Panzer, S., & Gremmel, T. (2018) · VASA · doi:10.1024/0301-1526/a000753 · Cited by 18

Authors: Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., Ardissino, D., Nicolau, J. C., Boden, W. E., Gurbel, P. A., Ruzyllo, W., Dalby, A. J., McGuire, D. K., Leiva-Pons, J. L., Parkhomenko, A., Gottlieb, S., Topacio, G. O., Hamm, C., Pavlides, G., Goudev, A. R., Oto, A., Tseng, C.-D., Merkely, B., Gasparovic, V., Corbalan, R., Cinteză, M., McLendon, R. C., Winters, K. J., Brown, E. B., Lokhnygina, Y., Aylward, P. E., Huber, K., Hochman, J. S., & Ohman, E. M.
Affiliations: Duke Medical Center (US)
University of Alberta (CA)
Duke University (US)
St. Michael's Hospital (CA)
Brigham and Women's Hospital (US)
University of Copenhagen (DK)
National Taiwan University (TW)
Eli Lilly (United States) (US)
Flinders University (AU)
ORCID: Roe, Matthew T.
Armstrong, Paul W.
Fox, Keith A.A.
White, Harvey D.
Prabhakaran, Dorairaj
Goodman, Shaun G.
Cornel, Jan H.
Bhatt, Deepak L.
Clemmensen, Peter
Ardissino, Diego
Boden, William E.
Gurbel, Paul A.
McGuire, Darren K.
Leiva-Pons, Jose L.
Parkhomenko, Alexander
Gottlieb, Shmuel
Hamm, Christian
Goudev, Assen R.
Oto, Ali
Aylward, Philip E.
Huber, Kurt
Hochman, Judith S.
Ohman, E. Magnus
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-10-04
Volume: 367
Issue: 14
Pages: 1297-1309
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1205512
OpenAlex: W2109577952
Cited by: 874
References: 18
Citations by year: 2026: 16 · 2025: 24 · 2024: 14 · 2023: 31 · 2022: 43 · 2021: 49 · 2020: 58 · 2019: 53 · 2018: 70 · 2017: 92 · 2016: 71 · 2015: 91 · 2014: 114 · 2013: 124 · 2012: 20
FWCI: 71.23
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
Trakya University's Institutional Open Access System (Trakya University) (submittedVersion, other-oa)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
ORBi (University of Liège) (submittedVersion)
Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Radboud Repository (Radboud University) (submittedVersion)
Funders: Abbott Laboratories
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
Amylin Pharmaceuticals
AstraZeneca
GlaxoSmithKline
Sanofi
Gilead Sciences
Helsinn
Boston Scientific Corporation
Boston VA Research Institute
Regeneron Pharmaceuticals
Amarin Corporation
Medicines Company
Regado Biosciences
Eisai
Astellas Pharma
Servier
Genentech
Janssen Pharmaceuticals
Daiichi Sankyo Europe
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: prasugrel, clopidogrel, acute coronary syndrome, non-ST-elevation myocardial infarction, unstable angina, platelet aggregation inhibition, antiplatelet therapy, bleeding risk, heart failure, cardiovascular mortality, stroke, elderly patients
MeSH terms: Prasugrel Hydrochloride, Clopidogrel, Aged, Angina, Unstable, Aspirin, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks